MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ
11.09
+1.22
+12.31%
Pre Market: 11.09 +0.01 +0.05% 07:00 03/28 EDT
OPEN
9.88
PREV CLOSE
9.87
HIGH
11.44
LOW
9.82
VOLUME
857
TURNOVER
0
52 WEEK HIGH
16.24
52 WEEK LOW
1.280
MARKET CAP
547.78M
P/E (TTM)
-4.6240
1D
5D
1M
3M
1Y
5Y
Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-hearted
TipRanks · 1d ago
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
TipRanks · 2d ago
Nkarta Price Target Raised to $16.00/Share From $15.00 by Canaccord Genuity
Dow Jones · 2d ago
Nkarta Is Maintained at Buy by Canaccord Genuity
Dow Jones · 2d ago
Canaccord Genuity Maintains Buy on Nkarta, Raises Price Target to $16
Benzinga · 2d ago
Stifel Nicolaus Keeps Their Buy Rating on Nkarta (NKTX)
TipRanks · 2d ago
Nkarta: NK Cell Therapy Advancement On Two Fronts
Nkarta, Inc. Is gearing up to report results from its phase 1 study using NKX019 for the treatment of patients with relapsed/refractory non-Hodgkin's lymphoma. The company is also advancing its allogeneic NK cell to treat patients with autoimmune disorders like Lupus Nephritis. The first patient is expected to be dosed in the 1st half of 2024. NKx019 is being used to target patients with the global non-hodgkins's lymphoma market expected to reach $20 billion by 2036.
Seeking Alpha · 2d ago
Nasdaq Turns Higher; Akanda Shares Plunge
U.S. Stocks traded mixed toward the end of trading on Monday. The Dow traded down 0.37% while the Nasdaq Composite turned higher. Energy shares jumped by 1% on Monday; industrials shares fell by 0.5%. Sales of new single-family houses in the U.S., fell by 662,000 in February. Asian markets closed lower; European shares mostly higher.
Benzinga · 2d ago
More
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.

Webull offers Nkarta Inc stock information, including NASDAQ: NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.